Racotumomab monoclonal antibody is a murine anti-idiotypic antibody. This monoclonal antibody mimics N-glycolyl-GM3 gangliosides has been tested in several clinical trials Phase I/II for breast, melanoma and non-small...Racotumomab monoclonal antibody is a murine anti-idiotypic antibody. This monoclonal antibody mimics N-glycolyl-GM3 gangliosides has been tested in several clinical trials Phase I/II for breast, melanoma and non-small cell lung cancer patients as an anti-idiotypic cancer vaccine. The early production process was performed in vivo from mice ascites fluid. This process was transferred to bioreactor-based method at pilot scale followed to the scale-up of the fermentation. In this work we present a comprehensive molecular characterization of racotumomab MAb produced by the two different production scales in order to determine the impact of the manufacturing process in vaccine performance. We observed differences in glycosylation pattern and charge heterogeneity between racotumomab produced in both scales. Interestingly, these modifications had no significant impact on biological activity elicited in chickens. So, changes in primary structure like glycosylation, charge heterogeneity and oxidation did not affect biological activity of the vaccine.展开更多
In this paper,we investigate the comparability structure over exchange rings.It is shownthat the subdirect product of an exchange ring with stable range one and an exchange ring satisfyingthe comparability is also an ...In this paper,we investigate the comparability structure over exchange rings.It is shownthat the subdirect product of an exchange ring with stable range one and an exchange ring satisfyingthe comparability is also an exchange ring satisfying the comparability.This provides a new classof exchange rings satisfying the comparability.Furthermore,we investigate the s-comparability overexchange rings.This generalizes the corresponding results of Goodearl and Chen.展开更多
目的:评估2011—2020年四川省结核病防治经费投入产生的社会效益,为制定新时期中长期发展规划提供参考依据。方法:采用回顾性研究方法,从“结核病管理信息系统”和“传染病监测”系统中收集四川省2011—2020年(“十二五”和“十三五”期...目的:评估2011—2020年四川省结核病防治经费投入产生的社会效益,为制定新时期中长期发展规划提供参考依据。方法:采用回顾性研究方法,从“结核病管理信息系统”和“传染病监测”系统中收集四川省2011—2020年(“十二五”和“十三五”期间)涂阳肺结核患者治疗转归情况和肺结核患者劳动人口比例,结合四川省统计年鉴和全国结核病防治规划终期评估规划自评调查表等获取经费资料和人均国内生产总值(GDP),采用卫生经济学中常用的成本-效果、成本-效用、成本-效益等3种分析方法估算10年间结核病防治经费投入的社会效果、社会效用和社会效益,并对比分析“十二五”和“十三五”期间的估算结果。结果:2011—2020年,四川省共投入结核病防治经费76032.60万元,成功治疗涂阳肺结核患者160167例,避免了696899名健康人受到传染,挽救了1155277个伤残调整寿命年(disability adjusted life year,DALY),为社会节约医疗费用6.05亿元,挽回社会经济损失约370.32亿元。每投入1091.01元即可避免1名健康人被传染,每投入658.13元即可挽回1个DALY,每投入1元即可产生49.50元的社会经济效益。“十三五”期间带来的总社会效益(209.22亿元)较“十二五”期间(167.14亿元)增长了25.18%[(209.22-167.14)/167.14],但政府每投入1元的结核病防治经费产生的社会效益(47.56元)较“十二五”期间(52.17元)减少了4.61元。结论:2011—2020年间各级政府和国际项目对四川省结核病防控工作投入的经费产生了较好的社会效果、效用和效益。建议在保持目前经费投入力度的基础上,各级政府进一步加大投入,尤其对病原学阳性肺结核患者的发现和治疗管理力度,以期产生更高的社会效益。展开更多
文摘Racotumomab monoclonal antibody is a murine anti-idiotypic antibody. This monoclonal antibody mimics N-glycolyl-GM3 gangliosides has been tested in several clinical trials Phase I/II for breast, melanoma and non-small cell lung cancer patients as an anti-idiotypic cancer vaccine. The early production process was performed in vivo from mice ascites fluid. This process was transferred to bioreactor-based method at pilot scale followed to the scale-up of the fermentation. In this work we present a comprehensive molecular characterization of racotumomab MAb produced by the two different production scales in order to determine the impact of the manufacturing process in vaccine performance. We observed differences in glycosylation pattern and charge heterogeneity between racotumomab produced in both scales. Interestingly, these modifications had no significant impact on biological activity elicited in chickens. So, changes in primary structure like glycosylation, charge heterogeneity and oxidation did not affect biological activity of the vaccine.
基金This work is supported by the National Natural Science Foundation of China (Grant No.19801012)the Ministry of Education of China.
文摘In this paper,we investigate the comparability structure over exchange rings.It is shownthat the subdirect product of an exchange ring with stable range one and an exchange ring satisfyingthe comparability is also an exchange ring satisfying the comparability.This provides a new classof exchange rings satisfying the comparability.Furthermore,we investigate the s-comparability overexchange rings.This generalizes the corresponding results of Goodearl and Chen.
文摘目的:评估2011—2020年四川省结核病防治经费投入产生的社会效益,为制定新时期中长期发展规划提供参考依据。方法:采用回顾性研究方法,从“结核病管理信息系统”和“传染病监测”系统中收集四川省2011—2020年(“十二五”和“十三五”期间)涂阳肺结核患者治疗转归情况和肺结核患者劳动人口比例,结合四川省统计年鉴和全国结核病防治规划终期评估规划自评调查表等获取经费资料和人均国内生产总值(GDP),采用卫生经济学中常用的成本-效果、成本-效用、成本-效益等3种分析方法估算10年间结核病防治经费投入的社会效果、社会效用和社会效益,并对比分析“十二五”和“十三五”期间的估算结果。结果:2011—2020年,四川省共投入结核病防治经费76032.60万元,成功治疗涂阳肺结核患者160167例,避免了696899名健康人受到传染,挽救了1155277个伤残调整寿命年(disability adjusted life year,DALY),为社会节约医疗费用6.05亿元,挽回社会经济损失约370.32亿元。每投入1091.01元即可避免1名健康人被传染,每投入658.13元即可挽回1个DALY,每投入1元即可产生49.50元的社会经济效益。“十三五”期间带来的总社会效益(209.22亿元)较“十二五”期间(167.14亿元)增长了25.18%[(209.22-167.14)/167.14],但政府每投入1元的结核病防治经费产生的社会效益(47.56元)较“十二五”期间(52.17元)减少了4.61元。结论:2011—2020年间各级政府和国际项目对四川省结核病防控工作投入的经费产生了较好的社会效果、效用和效益。建议在保持目前经费投入力度的基础上,各级政府进一步加大投入,尤其对病原学阳性肺结核患者的发现和治疗管理力度,以期产生更高的社会效益。
